Endpoints News 生物医药· Kyle LaHucik·· 16 天前AI 评分41
明慧生物将甲状腺眼病药物在日本的权利出售给百年药企
China biotech Minghui does thyroid eye disease deal for $110M upfront
AI 导读
明慧生物将其处于III期临床试验的甲状腺眼病药物在日本的权利以1.1亿美元的价格出售给了一家百年专业药企。
正文
A Chinese biotech is selling the Japanese rights for its Phase 3 thyroid eye disease drug to a 106-year-old specialty pharma long known for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news